Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers

Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against